Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Publications Donath Marc

Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.

Hepprich M; Mudry JM; Gregoriano C; Jornayvaz FR; Carballo S; Wojtusciszyn A; Bart PA; Chiche JD; Fischli S; Baumgartner T; Cavelti-Weder C; Braun DL; Günthard HF; Beuschlein F; Conen A; West E; Isenring E; Zechmann S; Bucklar G; Aubry Y; Dey L; Müller B; Hunziker P; Schütz P; Cattaneo M; Donath MY. EClinicalMedicine. 2022.

Inflammation in obesity, diabetes, and related disorders.

Rohm TV; Meier DT; Olefsky JM; Donath MY. Immunity. 2022.

Prohormone convertase 1/3 deficiency causes obesity due to impaired proinsulin processing.

Meier DT; Rachid L; Wiedemann SJ; Traub S; Trimigliozzi K; Stawiski M; Sauteur L; Winter DV; Le Foll C; Brégère C; Guzman R; Odermatt A; Böni-Schnetzler M; Donath MY. Nature Communications. 2022.

The cephalic phase of insulin release is modulated by IL-1β.

Wiedemann SJ; Trimigliozzi K; Dror E; Meier DT; Molina-Tijeras JA; Rachid L; Le Foll C; Magnan C; Schulze F; Stawiski M; Häuselmann SP; Méreau H; Böni-Schnetzler M; Donath MY. Cell Metabolism. 2022.

Type 1 diabetes: what is the role of autoimmunity in β cell death?

Donath MY. Journal of Clinical Investigation. 2022.

Author Correction: A guiding map for inflammation.

Netea MG; Balkwill F; Chonchol M; Cominelli F; Donath MY; Giamarellos-Bourboulis EJ; Golenbock D; Gresnigt MS; Heneka MT; Hoffman HM; Hotchkiss R; Joosten LAB; Kastner DL; Korte M; Latz E; Libby P; Mandrup-Poulsen T; Mantovani A; Mills KHG; Nowak KL; O'Neill LA; Pickkers P; van der Poll T; Ridker PM; Schalkwijk J; Schwartz DA; Siegmund B; Steer CJ; Tilg H; van der Meer JWM; van de Veerdonk FL; Dinarello CA. . 2021.

Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome

Ebrahimi F.; Urwyler S.A.; Betz M.J.; Christ E.R.; Schuetz P.; Mueller B.; Donath M.Y.; Christ-Crain M.. Scientific Reports. 2021.

Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?

Donath MY. Cell Metabolism. 2021.

IL-1beta promotes the age-associated decline of beta cell function.

Böni-Schnetzler M; Méreau H; Rachid L; Wiedemann SJ; Schulze F; Trimigliozzi K; Meier DT; Donath MY. iScience. 2021.

Il-6 receptor blockade increases circulating adiponectin levels in people with obesity: An explanatory analysis

Wueest S.; Seelig E.; Timper K.; Lyngbaek M.P.; Karstoft K.; Donath M.Y.; Ellingsgaard H.; Konrad D.. Metabolites. 2021.

Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia

Schiavon M.; Herzig D.; Hepprich M.; Donath M.Y.; Bally L.; Dalla Man C.. Frontiers in Endocrinology. 2021.

Predictors of Postprandial Hypoglycemia After Gastric Bypass Surgery: a Retrospective Case-Control Study

Zweck E.; Hepprich M.; Donath M.Y.. Obesity surgery. 2021.

Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study

Hepprich M.; Zillig D.; Florian-Reynoso M.A.; Donath M.Y.; Rudofsky G.. Diabetes Therapy. 2021.

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.

Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR; SEMIRA collaborators. The Lancet. 2020.

Distinct Transcriptional Responses across Tissue-Resident Macrophages to Short-Term and Long-Term Metabolic Challenge.

Brykczynska U; Geigges M; Wiedemann SJ; Dror E; Böni-Schnetzler M; Hess C; Donath MY; Paro R. Cell Reports. 2020.

Evidence for cephalic phase insulin release in humans: A systematic review and meta-analysis.

Wiedemann SJ; Rachid L; Illigens B; Böni-Schnetzler M; Donath MY. APPETITE. 2020.

GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study

Ellingsgaard H.; Seelig E.; Timper K.; Coslovsky M.; Soederlund L.; Lyngbaek M.P.; Wewer Albrechtsen N.J.; Schmidt-Trucksass A.; Hanssen H.; Frey W.O.; Karstoft K.; Pedersen B.K.; Boni-Schnetzler M.; Donath M.Y.. Diabetologia. 2020.

IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1-7]) and Decreases Blood Pressure in Obese Individuals.

Urwyler SA; Ebrahimi F; Burkard T; Schuetz P; Poglitsch M; Mueller B; Donath MY; Christ-Crain M. Hypertension. 2020.

Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes.

Schulze F; Wehner J; Kratschmar DV; Makshana V; Meier DT; Häuselmann SP; Dalmas E; Thienel C; Dror E; Wiedemann SJ; Traub S; Nordmann TM; Rachid L; De Baat A; Rohm TV; Zhao C; Odermatt A; Böni-Schnetzler M; Donath MY. Scientific Reports. 2020.

Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia.

Hepprich M; Donath MY; Hemkens LG. BMC Medical Research Methodology. 2020.

Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β.

Hepprich M; Wiedemann SJ; Schelker BL; Trinh B; Stärkle A; Geigges M; Löliger J; Böni-Schnetzler M; Rudofsky G; Donath MY. Cell Metabolism. 2020.

Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153-e154.

Trinh B; Donath MY; Läubli H. . 2020.

The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome.

Popovic M; Ebrahimi F; Urwyler SA; Donath MY; Christ-Crain M. Endocrine connections. 2020.

Designer cytokine for the treatment of diabetes.

Donath MY. Nature metabolism. 2019.

Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial.

Ebrahimi F; Urwyler SA; Schuetz P; Mueller B; Bernasconi L; Neyer P; Donath MY; Christ-Crain M. Endocrine connections. 2019.

Exercise and the dipeptidyl-peptidase IV inhibitor sitagliptin do not improve beta-cell function and glucose homeostasis in long-lasting type 1 diabetes-A randomised open-label study.

Seelig E; Trinh B; Hanssen H; Schmid-Trucksäss A; Ellingsgaard H; Christ-Crain M; Donath MY. Endocrinology, diabetes & metabolism. 2019.

Exercise upregulates copeptin levels which is not regulated by interleukin-1.

Popovic M; Timper K; Seelig E; Nordmann T; Erlanger TE; Donath MY; Christ-Crain M. PLoS One. 2019.

Inflammation and type 2 diabetes: from basic science to treatment.

Donath MY. . 2019.

Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.

Donath MY; Meier DT; Böni-Schnetzler M. Endocrine reviews. 2019.

Proteomic Landscape of Aldosterone-Producing Adenoma.

Swierczynska MM; Betz MJ; Colombi M; Dazert E; Jenö P; Moes S; Pfaff C; Glatz K; Reincke M; Beuschlein F; Donath MY; Hall MN. Hypertension. 2019.

Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab.

Trinh B; Donath MY; Läubli H. Diabetes care. 2019.

Targeting innate immune mediators in type 1 and type 2 diabetes.

Donath MY; Dinarello CA; Mandrup-Poulsen T. Nature reviews. Immunology. 2019.

Treatment of Primary Aldosteronism With mTORC1 Inhibitors.

Trinh B; Hepprich M; Betz MJ; Burkard T; Cavelti-Weder C; Seelig E; Meienberg F; Kratschmar DV; Beuschlein F; Reincke M; Odermatt A; Hall MN; Donath MY; Swierczynska MM. Journal of Clinical Endocrinology and Metabolism. 2019.

Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.

Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM. Journal of the American College of Cardiology. 2018.

First Experiences With a Wearable Multisensor Device in a Noninvasive Continuous Glucose Monitoring Study at Home, Part II: The Investigators' View.

Zanon M; Mueller M; Zakharov P; Talary MS; Donath M; Stahel WA; Caduff A. Journal of diabetes science and technology. 2018.

First Experiences With a Wearable Multisensor in an Outpatient Glucose Monitoring Study, Part I: The Users' View.

Caduff A; Zanon M; Zakharov P; Mueller M; Talary M; Krebs A; Stahel WA; Donath M. Journal of diabetes science and technology. 2018.

IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial.

Ebrahimi F; Urwyler SA; Straumann S; Doerpfeld S; Bernasconi L; Neyer P; Schuetz P; Mueller B; Donath MY; Christ-Crain M. Journal of Clinical Endocrinology and Metabolism. 2018.

IL-6-Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion.

Wueest S; Laesser CI; Böni-Schnetzler M; Item F; Lucchini FC; Borsigova M; Müller W; Donath MY; Konrad D. Diabetes. 2018.

The role of IL-1 in postprandial fatigue.

Lehrskov LL; Dorph E; Widmer AM; Hepprich M; Siegenthaler J; Timper K; Donath MY. Molecular Metabolism. 2018.

β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion.

Böni-Schnetzler M; Häuselmann SP; Dalmas E; Meier DT; Thienel C; Traub S; Schulze F; Steiger L; Dror E; Martin P; Herrera PL; Gabay C; Donath MY. Cell Reports. 2018.

[Abdominal pain and hypertension in a 55-year-old male patient].

Kofler T; Yueksel F; Dirnhofer S; Donath MY; Trendelenburg M. Der Internist. 2017.

A guiding map for inflammation.

Netea MG; Balkwill F; Chonchol M; Cominelli F; Donath MY; Giamarellos-Bourboulis EJ; Golenbock D; Gresnigt MS; Heneka MT; Hoffman HM; Hotchkiss R; Joosten LAB; Kastner DL; Korte M; Latz E; Libby P; Mandrup-Poulsen T; Mantovani A; Mills KHG; Nowak KL; O'Neill LA; Pickkers P; van der Poll T; Ridker PM; Schalkwijk J; Schwartz DA; Siegmund B; Steer CJ; Tilg H; van der Meer JWM; van de Veerdonk FL; Dinarello CA. Nature immunology. 2017.

IKKβ inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents.

Ivovic A; Oprescu AI; Koulajian K; Mori Y; Eversley JA; Zhang L; Nino-Fong R; Lewis GF; Donath MY; Karin M; Wheeler MB; Ehses J; Volchuk A; Chan CB; Giacca A. Diabetologia. 2017.

Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals

Urwyler, Sandrine Andrea; Schuetz, Philipp; Ebrahimi, Fahim; Donath, Marc Y.; Christ-Crain, Mirjam. Journal of Clinical Endocrinology and Metabolism. 2017.

Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid Production.

Dalmas E; Lehmann FM; Dror E; Wueest S; Thienel C; Borsigova M; Stawiski M; Traunecker E; Lucchini FC; Dapito DH; Kallert SM; Guigas B; Pattou F; Kerr-Conte J; Maechler P; Girard JP; Konrad D; Wolfrum C; Böni-Schnetzler M; Finke D; Donath MY. Immunity. 2017.

Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis.

Traub S; Meier DT; Schulze F; Dror E; Nordmann TM; Goetz N; Koch N; Dalmas E; Stawiski M; Makshana V; Thorel F; Herrera PL; Böni-Schnetzler M; Donath MY. Cell Reports. 2017.

Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation.

Dror E; Dalmas E; Meier DT; Wueest S; Thévenet J; Thienel C; Timper K; Nordmann TM; Traub S; Schulze F; Item F; Vallois D; Pattou F; Kerr-Conte J; Lavallard V; Berney T; Thorens B; Konrad D; Böni-Schnetzler M; Donath MY. Nature immunology. 2017.

The Role of Inflammation in β-cell Dedifferentiation.

Nordmann TM; Dror E; Schulze F; Traub S; Berishvili E; Barbieux C; Böni-Schnetzler M; Donath MY. Scientific Reports. 2017.

[Management of Type 2 Diabetes: a Practical Approach].

Donath M. Schweizerische Rundschau fur Medizin/Praxis. 2016.

Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications.

Pollack RM; Donath MY; LeRoith D; Leibowitz G. Diabetes care. 2016.

Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.

Cavelti-Weder C; Timper K; Seelig E; Keller C; Osranek M; Lässing U; Spohn G; Maurer P; Müller P; Jennings GT; Willers J; Saudan P; Donath MY; Bachmann MF. Molecular therapy : the journal of the American Society of Gene Therapy. 2016.

Empfehlungen zur Prävention, Diagnostik und Therapie des Delirs im Alter.

Savaskan E; Baumgartner M; Georgescu D; Hafner M; Hasemann W; Kressig RW; Popp J; Rohrbach E; Schmid R; Verloo H. Praxis. 2016.

Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells

Timper K.; Dalmas E.; Dror E.; Rutti S.; Thienel C.; Sauter N.S.; Bouzakri K.; Bedat B.; Pattou F.; Kerr-Conte J.; Boni-Schnetzler M.; Donath M.Y.. Gastroenterology. 2016.

Individualized treatment strategies for type 2 diabetes Individualisierte Behandlungsstrategien bei Diabetes mellitus Typ 2

Bendik C.F.; Donath M.Y.. Therapeutische Umschau. 2016.

Interleukin-1 antagonism in type 1 diabetes of long duration.

Seelig E; Timper K; Falconnier C; Stoeckli R; Bilz S; Oram R; McDonald TJ; Donath MY. DIABETES & METABOLISM. 2016.

Multiple benefits of targeting inflammation in the treatment of type 2 diabetes.

Donath MY. Diabetologia. 2016.

Angiotensin II induces interleukin-1b-mediated islet inflammation and β-cell dysfunction independently of vasoconstrictive effects

Sauter N.S.; Thienel C.; Plutino Y.; Kampe K.; Dror E.; Traub S.; Timper K.; Bedat B.; Pattou F.; Kerr-Conte J.; Jehle A.W.; Boni-Schnetzler M.; Donath M.Y.. Diabetes. 2015.

Interleukin-1 receptor antagonist: friend or foe to the heart?

Herder, Christian; Donath, Marc Y.. The lancet. Diabetes & endocrinology. 2015.

Muscle-derived IL-6 is not regulated by IL-1 during exercise. A double blind, placebo-controlled, randomized crossover study

Nordmann T.M.; Seelig E.; Timper K.; Cordes M.; Coslovsky M.; Hanssen H.; Schmidt-Trucksass A.; Donath M.Y.. PLoS One. 2015.

Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus

Timper K.; Seelig E.; Tsakiris D.A.; Donath M.Y.. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2015.

Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes.

Ehses JA; Donath MY. Diabetologia. 2015.

The Effect of a Global, Subject, and Device-Specific Model on a Noninvasive Glucose Monitoring Multisensor System.

Caduff A; Zanon M; Mueller M; Zakharov P; Feldman Y; De Feo O; Donath M; Stahel WA; Talary MS. Journal of diabetes science and technology. 2015.

The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications.

Herder C; Dalmas E; Böni-Schnetzler M; Donath MY. Trends in endocrinology and metabolism: TEM. 2015.

A role for interleukin-22 in the alleviation of metabolic syndrome.

Dalmas E; Donath MY. Nature medicine. 2014.

Fractalkine (CX3CL1), a new factor protecting β-cells against TNFα.

Rutti S; Arous C; Schvartz D; Timper K; Sanchez JC; Dermitzakis E; Donath MY; Halban PA; Bouzakri K. Molecular Metabolism. 2014.

Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicenter, randomized double-masked, placebo-controlled trials

Moran A.; Bundy B.; Becker D.J.; DiMeglio L.A.; Gitelman S.E.; Goland R.; Greenbaum C.J.; Herold K.C.; Marks J.B.; Raskin P.; Sanda S.; Schatz D.; Wherrett D.; Wilson D.M.; Krischer J.P.; Skyler J.S.; Pickersgill L.; De Koning E.; Ziegler A.-G.; Boehm B.; Badenhoop K.; Schloot N.; Bak J.F.; Pozzilli P.; Mauricio D.; Donath M.Y.; Castano L.; Wagner A.; Lervang H.H.; Perrild H.; Mandrup-Poulsen T.. Diabetes Technology and Therapeutics. 2014.

Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice

Wueest S.; Item F.; Boyle C.N.; Jirkof P.; Cesarovic N.; Ellingsgaard H.; Boni-Schnetzler M.; Timper K.; Arras M.; Donath M.Y.; Lutz T.A.; Schoenle E.J.; Konrad D.. American journal of physiology. Regulatory, integrative and comparative physiology. 2014.

Targeting inflammation in the treatment of type 2 diabetes: time to start

Donath, Marc Y.. Nature Reviews Drug Discovery. 2014.

What is the role of autoimmunity in type 1 diabetes? A clinical perspective.

Donath MY; Hess C; Palmer E. Diabetologia. 2014.

GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?

Donath, Marc Y.; Burcelin, Remy. Diabetes care. 2013.

How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes.

Böni-Schnetzler M; Donath MY. British journal of clinical pharmacology. 2013.

Identification of a SIRT1 mutation in a family with type 1 diabetes

Biason-Lauber A.; Boni-Schnetzler M.; Hubbard B.P.; Bouzakri K.; Brunner A.; Cavelti-Weder C.; Keller C.; Meyer-Boni M.; Meier D.T.; Brorsson C.; Timper K.; Leibowitz G.; Patrignani A.; Bruggmann R.; Boily G.; Zulewski H.; Geier A.; Cermak J.M.; Elliott P.; Ellis J.L.; Westphal C.; Knobel U.; Eloranta J.J.; Kerr-Conte J.; Pattou F.; Konrad D.; Matter C.M.; Fontana A.; Rogler G.; Schlapbach R.; Regairaz C.; Carballido J.M.; Glaser B.; McBurney M.W.; Pociot F.; Sinclair D.A.; Donath M.Y.. Cell Metabolism. 2013.

Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity.

Donath MY; Dalmas É; Sauter NS; Böni-Schnetzler M. Cell Metabolism. 2013.

Infliximab in the treatment of Crohn disease and type 1 diabetes.

Timper K; Hruz P; Beglinger C; Donath MY. Diabetes care. 2013.

Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials

Moran,Antoinette; Bundy,Brian; Becker,Dorothy J; DiMeglio,Linda A; Gitelman,Stephen E; Goland,Robin; Greenbaum,Carla J; Herold,Kevan C; Marks,Jennifer B; Raskin,Philip; Sanda,Srinath; Schatz,Desmond; Wherrett,Diane K; Wilson,Darrell M; Krischer,Jeffrey P; Skyler,Jay S; Type 1 Diabetes TrialNet Canakinumab Study Group; Pickersgill,Linda; de Koning,Eelco; Ziegler,Anette-G; Böehm,Bernhard; Badenhoop,Klaus; Schloot,Nanette; Bak,Jens Friis; Pozzilli,Paolo; Mauricio,Didac; Donath,Marc Y; Castaño,Luis; Wägner,Ana; Lervang,Hans Henrik; Perrild,Hans; Mandrup-Poulsen,Thomas; AIDA Study Group. The Lancet. 2013.

Susceptibility to fatty acid-induced β-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β-cell lipotoxicity and islet inflammation.

Tang C; Naassan AE; Chamson-Reig A; Koulajian K; Goh TT; Yoon F; Oprescu AI; Ghanim H; Lewis GF; Dandona P; Donath MY; Ehses JA; Arany E; Giacca A. Endocrinology. 2013.

Targeting inflammation in the treatment of type 2 diabetes.

Donath MY. Diabetes, obesity & metabolism. 2013.

Type 2 diabetes and islet inflammation

Donath M.Y.. . 2013.

When metabolism met immunology.

Donath MY. Nature immunology. 2013.

ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation.

Erener S; Mirsaidi A; Hesse M; Tiaden AN; Ellingsgaard H; Kostadinova R; Donath MY; Richards PJ; Hottiger MO. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012.

Cannabis exposure associated with weight reduction and β-cell protection in an obese rat model.

Levendal RA; Schumann D; Donath M; Frost CL. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2012.

Diabetes mellitus Type 2--the new face of an old lady.

Timper K; Donath MY. Swiss medical weekly. 2012.

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.

Cavelti-Weder C; Babians-Brunner A; Keller C; Stahel MA; Kurz-Levin M; Zayed H; Solinger AM; Mandrup-Poulsen T; Dinarello CA; Donath MY. Diabetes care. 2012.

In Vitro Proliferation of Adult Human Beta-Cells

Rutti, Sabine; Sauter, Nadine S.; Bouzakri, Karim; Prazak, Richard; Halban, Philippe A.; Donath, Marc Y.. PLoS One. 2012.

Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy

Cavelti-Weder C.; Muggli B.; Keller C.; Babians-Brunner A.; Biason-Lauber A.; Donath M.Y.; Schmid-Grendelmeier P.. Diabetes care. 2012.

[Drug-drug interactions with HIV treatments].

Mossdorf E; Marzolini C; Fasel D; Mello Fayet A; Blum C; Donath M; Battegay M. Praxis. 2011.

Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscle.

Bouzakri K; Plomgaard P; Berney T; Donath MY; Pedersen BK; Halban PA. Diabetes. 2011.

Characteristics of a multisensor system for non invasive glucose monitoring with external validation and prospective evaluation.

Caduff A; Mueller M; Megej A; Dewarrat F; Suri RE; Klisic J; Donath M; Zakharov P; Schaub D; Stahel WA; Talary MS. Biosensors & bioelectronics. 2011.

Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance?

Böni-Schnetzler M; Donath MY. CELL RESEARCH. 2011.

Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes.

Donath MY. Endocrinology. 2011.

Inhibition of IL-1beta improves fatigue in type 2 diabetes.

Cavelti-Weder C; Furrer R; Keller C; Babians-Brunner A; Solinger AM; Gast H; Fontana A; Donath MY; Penner IK. Diabetes care. 2011.

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

Ellingsgaard H; Hauselmann I; Schuler B; Habib AM; Baggio LL; Meier DT; Eppler E; Bouzakri K; Wueest S; Muller YD; Hansen AM; Reinecke M; Konrad D; Gassmann M; Reimann F; Halban PA; Gromada J; Drucker DJ; Gribble FM; Ehses JA; Donath MY. Nature medicine. 2011.

Subacute bilateral visual loss in methylmalonic acidemia.

Traber G; Baumgartner MR; Schwarz U; Pangalu A; Donath MY; Landau K. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2011.

Type 2 diabetes as an inflammatory disease.

Donath MY; Shoelson SE. Nature reviews. Immunology. 2011.

Blockade of interleukin 1 in type 1 diabetes mellitus.

Mandrup-Poulsen T; Pickersgill L; Donath MY. Nat Rev Endocrinol. 2010.

Cytokine production by islets in health and diabetes: cellular origin, regulation and function.

Donath MY; Böni-Schnetzler M; Ellingsgaard H; Halban PA; Ehses JA. Trends in endocrinology and metabolism: TEM. 2010.

Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice.

Wueest S; Rapold RA; Schumann DM; Rytka JM; Schildknecht A; Nov O; Chervonsky AV; Rudich A; Schoenle EJ; Donath MY; Konrad D. Journal of Clinical Investigation. 2010.

IL-1 family nomenclature.

Dinarello C; Arend W; Sims J; Smith D; Blumberg H; O'Neill L; Goldbach-Mansky R; Pizarro T; Hoffman H; Bufler P; Nold M; Ghezzi P; Mantovani A; Garlanda C; Boraschi D; Rubartelli A; Netea M; van der Meer J; Joosten L; Mandrup-Poulsen T; Donath M; Lewis E; Pfeilschifter J; Martin M; Kracht M; Muehl H; Novick D; Lukic M; Conti B; Solinger A; Kelk P; van de Veerdonk F; Gabel C. Nature immunology. 2010.

IL-1β activation as a response to metabolic disturbances.

Donath MY; Böni-Schnetzler M. Cell Metabolism. 2010.

Role of IL-1beta in type 2 diabetes.

Dinarello CA; Donath MY; Mandrup-Poulsen T. Curr Opin Endocrinol Diabetes Obes (ONLINE-AUSGABE). 2010.

Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet.

Ehses JA; Meier DT; Wueest S; Rytka J; Boller S; Wielinga PY; Schraenen A; Lemaire K; Debray S; Van Lommel L; Pospisilik JA; Tschopp O; Schultze SM; Malipiero U; Esterbauer H; Ellingsgaard H; Rütti S; Schuit FC; Lutz TA; Böni-Schnetzler M; Konrad D; Donath MY. Diabetologia. 2010.

FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication

Maedler K.; Fontana A.; Ris F.; Sergeev P.; Toso C.; Oberholzer J.; Lehmann R.; Bachmann F.; Tasinato A.; Spinas G.A.; Halban P.A.; Donath M.Y.. Proceedings of the National Academy of Sciences of the United States of America. 2002.